Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,404 across all filing types
Latest filing 2018-12-20 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
LYNPARZA MEETS PRIMARY ENDPOINT IN SOLO-3 TRIAL
Regulatory Filings
2018-12-20 English
PHASE III ROCKIES AND OLYMPUS ROXADUSTAT TRIALS
Regulatory Filings
2018-12-20 English
Lynparza meets primary endpoint in SOLO-3 trial
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and a date, followed by a headline announcing positive Phase III trial results for a drug (Lynparza). The text details clinical trial outcomes (ORR, PFS), quotes company executives, and provides extensive background on the drug, the trial design (SOLO-3), and the collaboration between AstraZeneca and MSD. The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a regulatory news service announcement, which serves as a general regulatory filing or press release regarding a significant corporate/clinical development, rather than a formal financial report (like 10-K or IR) or a transcript. Since it is a formal announcement distributed via the RNS system, the most appropriate classification is Regulatory Filings (RNS). It is not an Earnings Release (ER) as it focuses on clinical trial data, not period financial results.
2018-12-20 English
Phase III ROCKIES and OLYMPUS roxadustat trials
Earnings Release Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement distributed via the London Stock Exchange's news service (RNS). The content details the positive results of Phase III clinical trials (OLYMPUS and ROCKIES) for a drug (roxadustat) and mentions that this data will be part of a 'regulatory submission package'. This is a material corporate event announcement, but it is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a management discussion (MDA). Since it is a formal, time-sensitive announcement released through the RNS system, and it doesn't fit perfectly into the specific categories like ER (Earnings Release) or CAP (Financing Update), the most appropriate classification is the general regulatory announcement category, RNS, as it is explicitly sourced from RNS and serves as a primary information provider update. FY 2018
2018-12-20 English
FDA APPROVES LYNPARZA AS 1L MAINTENANCE THERAPY
Regulatory Filings
2018-12-19 English
FDA approves Lynparza as 1L maintenance therapy
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and a date, followed by a headline announcing an FDA approval for a drug (Lynparza) by AstraZeneca and MSD. The content details the approval, clinical trial results (SOLO-1), quotes from executives, and background information on the drug and disease. The presence of 'RNS Number' and the concluding statement referencing 'RNS, the news service of the London Stock Exchange' strongly indicates this is a regulatory news service announcement. Since this is a specific announcement of a regulatory event (FDA approval) and not a comprehensive periodic report (like 10-K or IR) or a general proxy/meeting material, it fits best under the general regulatory announcement category, RNS, as it is a direct communication via the RNS system.
2018-12-19 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.